Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database
Emilie Casarotto(Arysta LifeScience (France)), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Sheenu Chandwani(Merck & Co., Inc., Rahway, NJ, USA (United States)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Clara Allayous(Inserm), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, L. Verdoni, L. Lévy-Bachelot, G. Farge, Bastien Oriano(Hôtel-Dieu de Paris), Emilie Scherrer(Seagen (United States)), O. Dereure(Beth Israel Deaconess Medical Center)
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k